Abstract
Pfizer's deal with the Sanford-Burnham Medical Research Institute to identify and validate new drug targets to prevent and treat insulin resistance and organ damage in obesity-related diabetes could help reverse a trend that has seen the pharma arriving late—or not at all—to the party with new targets for the indication.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have